Best Peptides for Muscle Building: IGF-1, GHRP-6, and Growth Hormone Secretagogues

By Sam Smith

Skeletal muscle growth is regulated by three parallel biological axes — and understanding which peptides target which axis is the only way to think clearly about this research category. The GH axis (sermorelin, CJC-1295, ipamorelin, GHRP-6, tesamorelin) stimulates endogenous growth hormone release, which drives IGF-1 production in the liver and muscle tissue. The direct IGF-1 axis (IGF-1 LR3, MGF) bypasses the GH step entirely, activating the IGF-1 receptor and downstream mTOR signaling that drives protein synthesis. The myostatin pathway (follistatin 344) removes the brake — myostatin is a TGF-β family member that limits muscle fiber size, and blocking it produces hypertrophy that's genuinely striking in animal models: the Belgian Blue cattle with natural myostatin mutations and the documented “Bully Whippets” are genetic proof of how much muscle growth myostatin suppresses under normal conditions.

The research picture isn't uniformly positive across this category, and it's worth being clear about that. GH secretagogues have robust human data showing they raise GH and IGF-1 in dose-dependent fashion — the downstream muscle effects in healthy adults without GH deficiency are more modest than the hormone level changes might suggest. IGF-1 LR3's extended half-life (roughly 20 hours vs. 12 minutes for native IGF-1, achieved through an arginine substitution at position 3 and an N-terminal extension) makes it a useful probe for IGF-1 receptor biology, but the dose-response for muscle hypertrophy in non-deficient animals is complicated by receptor desensitization at higher doses. Follistatin's effects in animal models are dramatic; human translation remains an open question.

This guide covers what each of the major muscle-building peptides does mechanistically, how they compare with testosterone and anabolic steroids, which combination approaches have additive evidence behind them, what the safety profile looks like across the class, and what researchers need to consider when designing muscle hypertrophy studies.

What peptide is best for building muscle?

“Best” depends on the research endpoint. For overall lean muscle and muscle mass gains in rodent and small human studies, the CJC-1295 + ipamorelin GH-axis stack has the largest dataset. For direct skeletal muscle protein synthesis without GH-mediated pleiotropy, IGF-1 LR3 is most studied. For myostatin-pathway research and the largest absolute hypertrophy effects, follistatin 344 leads. For satellite-cell activation and post-injury repair, MGF (mechano growth factor) is the most specific. Selection of the specific peptide should match the research question rather than choosing on popularity.

Growth hormone secretagogues: CJC-1295, ipamorelin, GHRP-6

The growth hormone axis is the most-developed muscle building application in research peptides. CJC-1295 is a growth hormone-releasing hormone analogue that drives baseline GH and IGF-1 elevation. Ipamorelin is a selective GH secretagogue. According to the original PubMed-indexed ipamorelin paper, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release, meaning it does not also raise cortisol or prolactin the way older GHRPs (GHRP-2, GHRP-6) do.

The CJC-1295 and ipamorelin stack is the canonical research combination for support muscle growth research because it pairs a GHRH baseline-raiser with a pulse-triggering secretagogue. Together, they amplify the body’s natural growth hormone rhythm rather than imposing a flat elevation. The downstream effects on lean mass appear over 8 to 16 weeks of consistent dosing and are modest (a few percent gain) compared with anabolic steroid effects.

IGF-1 and MGF: direct muscle-targeting peptides

IGF-1 LR3 is a modified human growth hormone downstream effector: insulin-like growth factor-1 with an arginine substitution and a 13-amino acid N-terminal extension. Published research shows that a 13-amino acid extension appended to the N terminus of IGF-1 creates the LR3 variant with extended half-life and reduced IGF-binding-protein affinity, making more peptide available to bind muscle IGF-1 receptors and drive protein synthesis.

MGF (mechano growth factor) is a splice variant of IGF-1 produced in muscle after mechanical loading. Published research shows that MGF-E peptide significantly increases the proliferative life span and delays senescence of satellite cells, the resident stem-cell population that repairs and grows skeletal muscle after stress. MGF is the most specific muscle-repair peptide because it acts directly on satellite cell activation rather than on circulating GH/IGF-1.

Follistatin 344: myostatin inhibition

Myostatin (GDF-8) is the negative regulator of skeletal muscle growth. Published research shows that GDF-8 is a new member of the TGF-beta superfamily that limits the maximum achievable muscle mass through negative-feedback signalling. Animals with naturally occurring myostatin mutations (Belgian Blue cattle, “Bully Whippets”) show dramatic muscle hypertrophy as proof of concept.

Follistatin 344 binds myostatin in circulation and prevents its signalling. Published research shows that Follistatin is a myostatin-binding protein that can inhibit myostatin activity in vitro, with downstream effects on satellite-cell proliferation and muscle fibre hypertrophy. In rodent models, follistatin 344 produces the largest absolute lean-mass gains of any peptide in this guide.

Is BPC-157 good for building muscle?

BPC-157 is not primarily a muscle builder. The peptide acts on the eNOS-VEGF axis and is best characterised for tendon, ligament, gut mucosal, and angiogenic effects. It does not stimulate growth hormone, does not activate IGF-1 signalling, and does not inhibit myostatin. The compound is included in muscle-related stacks as a tissue repair adjunct (helping recover from training-induced micro-damage) rather than as a direct hypertrophic stimulus. For research focused on muscle growth specifically, the GH-axis or IGF-1 peptides cover the mechanism more directly.

How do peptides work for muscle growth?

Peptides for muscle growth work through specific receptor binding rather than the broad androgen-receptor activation that drives anabolic steroids:

• GH-axis peptides bind GHRH or ghrelin receptors on the pituitary, raising endogenous GH and downstream IGF-1 production
• IGF-1 LR3 and MGF bind the IGF-1 receptor directly on skeletal muscle, driving protein synthesis through PI3K-Akt-mTOR signaling
• Follistatin binds and neutralises myostatin in circulation, removing the negative-feedback brake
• BPC-157 and TB-500 act on tissue repair pathways to support recovery rather than direct hypertrophy

The selective pharmacology means peptides for muscle growth typically have narrower side-effect profiles than steroids but smaller absolute effect sizes on lean mass.

How do peptides differ from steroids?

Anabolic steroids (testosterone, nandrolone, trenbolone) activate the androgen receptor in muscle and many other tissues, producing broad anabolic, virilising, and cardiovascular effects. Research peptides for muscle building act on more specific axes:

• Effect magnitude: steroids produce 5 to 15 percent lean mass gains in weeks; peptides typically produce 2 to 5 percent over months
• Side-effect profile: steroids carry cardiovascular, hepatic, fertility, and psychiatric risks; peptides have far narrower side-effect signals
• Detection: steroids are detectable in standard sports-testing panels; many growth hormone secretagogues require specialised assays
• Mechanism: steroids work systemically through androgen-receptor activation; peptides work through tissue-specific signal pathways

Peptide therapies for muscle growth are not a steroid substitute in magnitude of effect; they cover a different region of the muscle-growth pharmacology landscape.

TRT vs peptides for muscle and recovery

Testosterone replacement therapy (TRT) is the clinical standard for diagnosed hypogonadism in adult men. It restores serum testosterone to the mid-normal range and produces modest lean-mass gains alongside other testosterone-driven effects. Peptide therapies for muscle growth are not approved alternatives to TRT for hypogonadism. The two could be combined research protocols (TRT for the hypogonadism, GH-axis peptides for additional GH/IGF-1 support), but TRT for muscle is the legally cleaner path within Canada and the United States. The peptides occupy a research-only niche.

Common peptide stacks for muscle

Canonical research stacks for support muscle development include:

• CJC-1295 + ipamorelin: the standard GH-axis stack, daily evening dosing
• CJC-1295 + ipamorelin + IGF-1 LR3: adds direct receptor stimulation for muscle-specific hypertrophy research
• Tesamorelin + ipamorelin: for body composition research with strong visceral-fat-reduction effect
• BPC-157 + TB-500: tissue repair adjunct for high-volume training research
• Follistatin 344 alone: highest-magnitude lean-mass research, less commonly stacked

How long does it take to see results?

GH-axis peptides produce measurable IGF-1 elevation within days but lean-mass changes over 8 to 16 weeks. IGF-1 LR3 produces faster results (4 to 8 weeks) because of the direct receptor mechanism. Follistatin 344 in rodent models produces visible hypertrophy by week 4 to 6 of dosing. MGF for satellite-cell research shows effects over 2 to 4 weeks. None of these peptides produces the next-day strength changes that some steroid users report; the mechanisms are gradual rather than acute.

Side effects and safety

Reported side effects in published rodent and small human research are minimal across the GH-axis peptides: injection-site irritation, occasional water retention, transient glucose elevation (because GH antagonises insulin signalling). IGF-1 LR3 carries the highest theoretical risk because of the broad mitogenic effects of IGF-1 on multiple tissues; chronic high-dose use is associated with concern about potential cancer-promoting effects, though no clear signal has emerged in published research. Follistatin 344 long-term effects on the multiple tissues that express activin (the broader TGF-β family ligand follistatin also binds) are not fully characterised.

Are peptides safe and legal for muscle building?

None of these peptides is approved by Health Canada or the FDA for muscle building. All are legal in Canada and the United States as research chemicals sold under research-use-only labelling. Most GH-axis peptides (CJC-1295, ipamorelin, sermorelin, GHRP-6, tesamorelin, MGF) are on the World Anti-Doping Agency prohibited list, banned in and out of competition. Follistatin and IGF-1 LR3 are also WADA-prohibited. Use in any sanctioned athletic context will fail testing.

Sourcing

Reproducible muscle growth research depends on the integrity of the input material:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace
• Mass spectrometry verification of the expected molecular weight for each compound
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies the canonical muscle-growth research peptides with COA and HPLC purity confirmation. View the CJC-1295 + Ipamorelin Blend, or browse the full peptide catalogue for IGF-1 LR3, MGF, follistatin 344, and tesamorelin.

Best peptides for muscle building questions

What peptide is best for building muscle?

CJC-1295 + ipamorelin for overall lean mass; IGF-1 LR3 for direct skeletal muscle protein synthesis; follistatin 344 for largest absolute hypertrophy effect. Selection depends on the research endpoint.

Is BPC-157 good for building muscle?

BPC-157 is not primarily a muscle builder. It acts on tissue repair and angiogenesis, making it useful as a recovery adjunct in training-research contexts but not as a direct hypertrophic stimulus.

What is better, TRT or peptides?

TRT is the approved clinical standard for hypogonadism in adult men. Peptide therapies for muscle growth are research-only and not an approved TRT alternative. The two cover different regulatory and biological niches.

How do peptides work for muscle growth?

Through specific receptor binding: GH-axis peptides on pituitary GHRH/ghrelin receptors, IGF-1 LR3 on skeletal muscle IGF-1 receptors, follistatin on circulating myostatin. The selective pharmacology produces smaller effects than steroids but narrower side-effect profiles.

Are peptides safe and legal for muscle building?

Legal in Canada and the United States as research chemicals only. Not approved for therapeutic use. Most are on the WADA prohibited list, making them unsuitable for sanctioned athletic competition.

Key data point: Rodriguez et al. (1995, Endocrinology) showed IGF-1 administration in hypophysectomised rats produced 45% greater muscle protein accretion than vehicle controls over 7 days, demonstrating that anabolic effects of the GH/IGF-1 axis on muscle can be reproduced independently of GH — the mechanistic basis for targeting IGF-1 directly in hypertrophy research rather than relying solely on upstream GHRH analogues.

Summary

The best peptides for muscle building in published research target the growth hormone axis (CJC-1295, ipamorelin, GHRP-6, sermorelin, tesamorelin), the IGF-1 axis (IGF-1 LR3, MGF), and the myostatin pathway (follistatin 344). Each class addresses a distinct bottleneck in skeletal muscle development. Selection should match research question to mechanism rather than choose on popularity. Effect sizes are modest compared with anabolic steroids but the side-effect profiles are narrower. All peptides on this list are research-only in Canada and the United States and most are WADA-prohibited. Source carefully, run factorial-control protocols, and treat each peptide as a specific mechanistic probe rather than a general anabolic agent.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption.